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Race and Risk of Subsequent Aggressive Breast Cancer 
Following Ductal Carcinoma in Situ
Ying Liu, MD, PhD 1,2; Robert West, MD3; Jason D. Weber, PhD2,4; and Graham A. Colditz, MD, DrPH1,2
BACKGROUND: General populations of black women have a higher risk of developing breast cancer negative for both estrogen 
receptor (ER) and progesterone receptor (PR) in comparison with white counterparts. Racial differences remain unknown in the 
risk of developing aggressive invasive breast cancer (IBC) that is characterized by negativity for both ER and PR (ER–PR–) or higher 
21-gene recurrence scores after ductal carcinoma in situ (DCIS). METHODS: This study identified 163,892 women (10.5% black, 9.8% 
Asian, and 8.6% Hispanic) with incident DCIS between 1990 and 2015 from the Surveillance, Epidemiology, and End Results data 
sets. Cox proportional hazards regression was used to estimate hazards ratios (HRs) of subsequent IBC classified by the hormone 
receptor status and 21-gene recurrence scores. RESULTS: During a median follow-up of 90 months, 8333 women developed IBC. In 
comparison with white women, the adjusted HR of subsequent ER–PR– breast cancer was 1.86 (95% confidence interval [CI], 1.57-
2.20) for black women (absolute 10-year difference, 2.2%) and 1.40 (95% CI, 1.14-1.71) for Asian women (absolute 10-year difference, 
0.4%); this was stronger than the associations for ER+ and/or PR+ subtypes (Pheterogeneity = .0004). The 21-gene recurrence scores 
of subsequent early-stage, ER+ IBCs varied by race/ethnicity (Pheterogeneity = .057); black women were more likely than white women 
to have a recurrence score of 26 or higher (HR, 1.38; 95% CI, 1.00-1.92). No significant difference was observed in the risks of subse-
quent IBC subtypes for Hispanic women. CONCLUSIONS: Black and Asian women with DCIS had higher risks of developing biologi-
cally aggressive IBC than white counterparts. This should be considered in treatment decisions for black and Asian patients with 
DCIS. Cancer 2019;125:3225-3233. © 2019 The Authors. Cancer published by Wiley Periodicals, Inc. on behalf of American Cancer 
Society. This is an open access article under the terms of the Creat ive Commo ns Attri butio n-NonCo mmerc ial-NoDerivs License, 
which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no 
modifications or adaptations are made. 
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INTRODUCTION
Ductal carcinoma in situ (DCIS), a nonobligate precursor to invasive breast cancer (IBC),1 currently constitutes 
20% to 30% of mammographically detected breast tumors.2,3 Approximately 64,000 new DCIS cases were expected 
to be diagnosed in the United States in 2018.2 Although the 10-year survival rate is higher than 98%,4 more than 10% 
of patients with DCIS develop a second breast tumor within 10 years of their diagnosis, and half of these are invasive.3
We and others have demonstrated a significant variation by race and ethnicity in the risk of developing breast 
cancer after DCIS. Compared with white women, black women are more likely to have second tumors (invasive and 
noninvasive) in either breast and die of IBC after DCIS.5-11 An increased risk of ipsilateral breast tumors has been 
observed in Hispanic women with DCIS,5,12 and an increased risk of contralateral breast tumors has been identified in 
Asian women with DCIS.5
In addition, our prior studies showed a higher proportion of estrogen receptor–positive (ER+) DCIS subtypes in 
black women than white women.5,6 However, black women with IBC who have no prior history of DCIS are far more 
likely than white counterparts to present with biologically aggressive features, including a lack of ER, progesterone 
receptor (PR), and human epidermal growth factor receptor 2 (HER2) expression and high RNA expression–based 
recurrence scores.13-15 It remains unknown whether black race (compared with white race) is associated with a higher 
risk of subsequently developing biologically aggressive breast cancer in patients with DCIS. In a large, racially diverse 
population of women with DCIS, we examined the risks of subsequent IBC subtypes, characterized by hormone recep-
tor status and 21-gene recurrence scores, by race and ethnicity.
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MATERIALS AND METHODS
Patient Population
Women with unilateral DCIS diagnosed between January 
1990 and June 2015 (n = 211,439) were identified from 
the 17 Surveillance, Epidemiology, and End Results 
(SEER) registries.12 The Alaska Native Tumor Registry 
was excluded because of the small number of Alaskan 
Native patients. A data-use agreement form was required 
before access to the deidentified data set. Because the dei-
dentified data were used, approval from the institutional 
review board of Washington University in St. Louis and 
patients’ informed consent were not required.
We excluded patients with a prior cancer history 
(n = 41,912) and those younger than 20 years (n = 19). 
Approximately 97% of eligible cases were white, black, 
Asian (not including Pacific Islanders), or Hispanic; thus, 
women of other races or unknown race (n = 5616) were 
excluded if they were non-Hispanic. The final sample size 
was 163,892. In the analysis of ipsilateral breast cancer, 
we also excluded patients treated with mastectomy for 
DCIS and those whose surgical treatment was unknown 
(n = 47,253). Women treated with prophylactic mas-
tectomy at initial DCIS (n = 9638) were also excluded 
from the analysis of contralateral breast cancer. Race and 
ethnicity were classified as non-Hispanic white (white), 
non-Hispanic black (black), non-Hispanic Asian (Asian), 
or Hispanic. Filipinos, Chinese, and Japanese were the 
3 largest Asian subgroups and accounted for 63.4% of 
Asian patients. The majority of the Hispanics (95.5%) 
were white, and thus Hispanic whites and Hispanic non-
whites were combined into a single group.
Covariates
Demographic factors included the age (20-39, 40-49, 
50-59, 60-69, or 70-84 years) and year of DCIS diagno-
sis (1990-1999, 2000-2009, or 2010-2015) and registries. 
Histopathological features of DCIS included the tumor 
size (<2 cm, 2-5 cm, ≥5 cm, or unknown), grade (well 
differentiated, moderately differentiated, poorly differ-
entiated, or unknown), and histologic pattern (comedo, 
papillary, cribriform, solid, or not otherwise specified). 
Tumor size was also categorized with the cutoffs of 1 and 
5 cm, and the results were similar (Supporting Table 1). 
Consistent with the literature,16 tumors were considered 
to be ER+ if the immunohistochemistry results of ER 
were positive or borderline. PR+ DCIS was similarly 
defined. Tumors positive for ER and/or PR were clas-
sified as hormone receptor–positive (ER+/PR+), and 
tumors negative for both ER and PR were classified as 
hormone receptor–negative (ER–PR–). Treatment for 
DCIS was categorized as no surgical treatment, breast-
conserving surgery alone, breast-conserving surgery plus 
radiation therapy, mastectomy, or unknown.
Outcomes
Subsequent breast cancer included IBC (reported to 
SEER registries) in either breast or metastatic breast can-
cer diagnosed at least 6 months after the initial DCIS. 
Ipsilateral IBCs were further classified as invasive recur-
rences arising in the same quadrant as the original DCIS 
and IBCs developing elsewhere in that same breast.17 
Theoretically, the latter have the same incidence and 
characteristics as IBCs developing in the contralateral 
breast. Thus, IBCs arising in the ipsilateral breast away 
from the original DCIS and in the contralateral breast 
were combined. IBC subtypes were similarly defined by 
both ER and PR. For IBC cases diagnosed between 2004 
and 2015, SEER data were linked to 21-gene recurrence 
score assay results from Genomic Health, Inc (Redwood 
City, California), by Information Management Services 
(Calverton, Maryland).18 IBC recurrence scores were 
categorized as low-risk (scores <18), intermediate-risk 
(scores = 18-30), or high-risk (scores ≥31).13-15 Because 
of the small number of racial minority patients who had 
21-gene recurrence scores, we combined intermediate- 
and high-risk scores. A prospective trial (Trial Assigning 
Individualized Options for Treatment [TAILORx]) 
has demonstrated that chemotherapy does not benefit 
patients with early-stage, hormone receptor–positive IBC 
whose 21-gene recurrence scores are less than 26.19 We 
also dichotomized recurrence scores with a cutoff of 26.
Statistical Analysis
Baseline characteristics across racial/ethnic groups were 
compared with Pearson chi-square tests for categorical 
variables and with an analysis of variance for continu-
ous variables. Cox proportional hazards regression was 
used to compute race-associated hazard ratios (HRs) 
and 95% confidence intervals (CIs) for subsequent IBC 
subtypes, and they were adjusted for the receptor status 
in the initial DCIS and the aforementioned covariates. 
Person-years were calculated from 6 months after the ini-
tial DCIS to the date of subsequent breast cancer, death, 
or December 31, 2015, whichever occurred first. A miss-
ing ER and PR status for subsequent IBC was consid-
ered for censoring. The assumption of proportionality 
for Cox models was confirmed with scaled Schoenfeld 
residuals. To determine whether race/ethnicity was dif-
ferentially associated with IBC subtypes, an extension of 
the Cox proportional hazards regression models was used 
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to estimate the separate associations of race/ethnicity 
with the relative hazard of each subtype. Specifically, we 
used the approach proposed by Lunn and McNeil,20,21 
in which each patient had a separate observation for 
each type of outcome and the analysis was stratified on 
outcome types. The initial full model assumed different 
associations of race/ethnicity and covariates with IBC 
subtypes. In a reduced model, race/ethnicity was con-
strained to have a single estimate across cancer subtypes, 
and the effects of covariates were allowed to be differ-
ent. Likelihood ratio tests for heterogeneity were used to 
determine statistically significant differences in the asso-
ciations of race/ethnicity with cancer subtypes. All statis-
tical analyses were performed with SAS (version 9.4; SAS 
Institute, Cary, North Carolina). Statistical significance 
was assessed as a 2-sided P value < .05.
HER2 data were collected for breast cancers diag-
nosed after 2009. A secondary analysis was performed to 
compare the risks of subsequent IBC classified by ER, 
PR, and HER2. Subsequent breast cancers occurring 
before 2010 were analyzed as censoring.
RESULTS
Among 163,892 women with DCIS, 71.0% were non-
Hispanic white, 10.5% were non-Hispanic black, 9.8% 
were non-Hispanic Asian, and 8.6% were Hispanic. 
Compared with white women, racial/ethnic minor-
ity women were younger at the initial DCIS and were 
more likely to have large, well-to-moderately differenti-
ated, noncomedo lesions (each P value < .0001; Table 1). 
Black and Asian women underwent mastectomy more 
frequently than white and Hispanic women (P < .0001). 
The ER and PR status for the initial DCIS was avail-
able for 60.3% and 56.8% of cases, respectively. The fre-
quency of ER–PR– DCIS was lower in the black group 
(11.4%) than other racial groups (white, 14.2%; Asian, 
13.8%; Hispanic, 13.4%; P < .0001; Table 1).
During a median follow-up of 90 months, 8333 
women developed IBC in either breast or metastatic 
breast cancer, and 7746 of these women (93.0%) had the 
ER and/or PR status available for their IBC. In compari-
son with white women, the overall risk of subsequent IBC 
was significantly increased in black women (HR, 1.42; 
95% CI, 1.32-1.52; absolute 10-year risk difference, 2.2%; 
95% CI, 1.7%-2.7%) but not in Asian women (HR, 
1.08; 95% CI, 0.99-1.17; absolute 10-year risk difference, 
0.4%; 95% CI, –0.1% to 0.8%) or Hispanic women (HR, 
1.09; 95% CI, 1.00-1.18; absolute 10-year risk difference, 
0.5%; 95% CI, 0%-1.0%). The associations were much 
stronger for ER–PR– subtypes than ER+/PR+ subtypes 
(Pheterogeneity = .0004; Table 2). In comparison with white 
women, the multivariable-adjusted HR of ER–PR– IBC 
was 1.86 (95% CI, 1.57-2.20) in black women, 1.40 
(95% CI, 1.14-1.71) in Asian women, and 1.24 (95% CI, 
1.00-1.54) in Hispanic women. Black women also had 
a significantly higher risk of subsequent triple-negative 
(negative for ER, PR, and HER2) breast cancer (HR, 
1.99; 95% CI, 1.44-2.75), and Asian women had a sig-
nificantly higher risk of subsequent HER2+ breast can-
cer (HR, 1.85; 95% CI, 1.21-2.84; Supporting Table 2).
We further examined the risks separately for ipsi-
lateral and contralateral IBC by race/ethnicity (Table 2). 
In comparison with white women, the risk of ipsilateral 
IBC was significantly higher in black (HR, 1.65; 95% CI, 
1.49-1.83; absolute 10-year risk difference, 2.1%; 95% CI, 
1.6%-2.6%), Asian (HR, 1.23; 95% CI, 1.09-1.38; abso-
lute 10-year risk difference, 0.7%; 95% CI, 0.3%-1.2%), 
and Hispanic women (HR, 1.19; 95% CI, 1.05-1.35; ab-
solute 10-year risk difference, 0.6%; 95 CI, 0.2%-1.1%). 
There was no significant heterogeneity in the associations 
for risks of ipsilateral cancer subtypes (Pheterogeneity = .57; 
Table 2). The multivariable-adjusted HR for ipsilateral 
ER–PR– subtypes was 1.83 (95% CI, 1.43-2.35) in black 
women, 1.34 (95% CI, 0.99-1.81) in Asian women, and 
1.40 (95% CI, 1.05-1.87) in Hispanic women.
In comparison with white women, the risk of 
contralateral IBC was significantly increased in black 
women (HR, 1.18; 95% CI, 1.07-1.31; absolute 10-year 
risk difference, 0.6%; 95% CI, 0.2%-0.9%). This asso-
ciation was much stronger for ER–PR– subtypes (HR, 
1.97; 95% CI, 1.55-2.52) than ER+/PR+ subtypes (HR, 
1.07; 95% CI, 0.95-1.20; Pheterogeneity < .0001). Although 
the risk of overall contralateral IBC was similar between 
Asian and white women (HR, 0.97; 95% CI, 0.86-1.10; 
absolute 10-year risk difference, 0.1%; 95% CI, –0.4% 
to 0.3%), Asian women had a significantly higher risk of 
ER–PR– subtypes (HR, 1.61; 95% CI, 1.20-2.16). The 
risks of overall contralateral breast cancer and subtypes 
were all comparable between Hispanic and white women.
Subsequent breast cancers were also categorized on 
the basis of both the laterality and locations of the orig-
inal DCIS and subsequent IBC (Table 3). Among 3010 
cases with known locations for both the original DCIS 
and subsequent ipsilateral IBC, 21.4% developed IBC 
in the same quadrant of the same breast as the origi-
nal DCIS. Compared with white women, black women 
had significantly higher risks of developing IBC in the 
same quadrant of the same breast as the original DCIS 
(HR, 1.51; 95% CI, 1.18-1.93; absolute 10-year risk 
difference, 0.3%; 95% CI, 0.1%-0.5%) and IBC in the 
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ipsilateral breast away from the original DCIS and in 
the contralateral breast (HR, 1.34; 95% CI, 1.24-1.45; 
absolute 10-year risk difference, 1.5%; 95% CI, 1.1%-
2.0%). The increased risk of IBC in the ipsilateral 
breast away from the original DCIS and in the con-
tralateral breast was much stronger for ER–PR– sub-
types (HR, 1.93; 95% CI, 1.60-2.40) than ER+/PR+ 
subtypes (HR for ER+/PR+, 1.24; 95% CI, 1.13-1.36) 
in black women (Pheterogeneity < .0001). In comparison 
with white women, the risk was significantly increased 
for ER–PR– IBC developing in the ipsilateral breast 
away from the original DCIS and in the contralateral 
breast in Asian women (HR, 1.45; 95% CI, 1.15-1.82) 
but not for ER+/PR+ subtypes (HR, 0.99; 95% CI, 
0.89-1.10). There was no significant difference in the 
risk of developing IBC in the same quadrant of the 
TABLE 1. Age and Age-Standardized Characteristics of Women With Unilateral DCIS in SEER by Race and 
Ethnicity (n = 163,892), 1990-2015
White Black Asian Hispanic Pa 
No. of cases 116,431 17,274 16,039 14,148
Age, mean (SD), y 59.5 (12.4) 58.3 (12.2) 56.4 (11.7) 56.2 (11.8) <.0001
Age at diagnosis, %
20-39 y 3.1 4.4 4.5 4.8
40-49 y 20.9 21.5 27.5 28.1
50-59 y 27.8 29.2 30.0 29.9
60-69 y 24.9 25.5 22.8 21.9
≥70 y 23.3 19.5 15.2 15.3 <.0001
Length of follow-up, median (range), mo 95 (6-311) 79 (6-311) 83 (6-311) 75 (6-311) <.0001
Length of follow-up, %
6-11 mo 3.3 4.8 5.0 5.9
12-59 mo 27.0 33.8 32.0 35.1
60-119 mo 31.3 32.5 30.9 31.9
≥120 mo 38.4 28.8 32.1 27.2 <.0001
Year of first DCIS diagnosis, %
1990-1999 17.0 12.7 14.3 10.1
2000-2009 53.3 49.9 48.3 49.3
2010-2015 29.7 37.4 37.5 40.6 <.0001
Histologic subtype, %
Not otherwise specified 66.9 68.4 67.5 68.3
Comedo 13.5 11.4 11.8 11.6
Papillary 5.2 7.0 5.0 5.4
Cribriform 8.5 8.2 10.0 9.4
Solid 5.9 5.0 5.8 5.3 <.0001
Grade, %
Well differentiated 13.7 16.6 14.1 14.3
Moderately differentiated 40.0 43.3 43.3 43.6
Poorly differentiated 46.3 40.1 42.6 42.1 <.0001
Tumor size, %
<2.0 cm 75.3 69.9 69.2 70.0
2.0-4.9 cm 19.2 21.8 24.9 22.8
≥5.0 cm 5.5 8.3 5.9 7.2 <.0001
ER, %
Negative 15.9 12.9 15.5 14.9
Positive 84.1 87.1 84.5 85.1 <.0001
PR, %
Negative 26.1 21.9 23.9 24.7
Positive 73.9 78.1 76.1 75.3 <.0001
Hormone receptor status, %
ER– and PR– 14.2 11.4 13.8 13.4
ER+ or PR+ 85.8 88.6 86.2 86.6 <.0001
Treatment for primary DCIS, %
No surgery 2.2 3.4 2.1 3.0
BCS alone 24.7 23.4 23.0 26.2
BCS and radiation 44.3 43.6 44.0 43.7
Mastectomy 28.9 29.5 31.0 27.1 <.0001
Abbreviations: BCS, breast-conserving surgery; DCIS, ductal carcinoma in situ; ER, estrogen receptor; PR, progesterone receptor; SD, standard deviation; 
SEER, Surveillance, Epidemiology, and End Results.
Race and ethnicity were classified into mutually exclusive categories: non-Hispanic white (hereafter called white), non-Hispanic Black (black), non-Hispanic 
Asian (Asian), and Hispanic (Hispanic). Supporting Table 6 shows distributions of missing values for each variable across race groups. Due to rounding, per-
centages did not always add up to 100%.
aP values were calculated from comparisons across all groups except for groups with missing values.
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same breast as the original DCIS, in a different quad-
rant of the same breast, or in the contralateral breast 
between Hispanic and white women.
Among 5045 patients with DCIS who subse-
quently developed early-stage (I, II, or IIIa), ER+ IBC 
between 2004 and 2015, 1184 (23.5%) had 21-gene 
TABLE 2. Adjusted HRs of Subsequent IBC Classified by Laterality and Hormone Receptor Status 
According to Race and Ethnicity in Women With DCIS in SEER, 1990-2015
Person-y
All Second Invasive Eventsa ER+ or PR+ ER– and PR–
Cases, No. HRb (95% CI) Cases, No. HRb (95% CI) Cases, No. HRb (95% CI)
Subsequent IBCc White 1,018,475 5884 1.00 4653 1.00 821 1.00
Black 129,931 1002 1.42 (1.32-1.52) 720 1.31 (1.21-1.43) 190 1.86 (1.57-2.20)
Asian 128,657 807 1.08 (0.99-1.17) 620 1.01 (0.92-1.11) 135 1.40 (1.14-1.71)
Hispanic 102,614 640 1.09 (1.00-1.18) 505 1.09 (0.99-1.20) 102 1.24 (1.00-1.54)
Pheterogeneity = .0004
Ipsilateral IBCd White 709,275 2438 1.00 1846 1.00 393 1.00
Black 89,081 478 1.65 (1.49-1.83) 341 1.58 (1.40-1.78) 86 1.83 (1.43-2.35)
Asian 86,294 378 1.23 (1.09-1.38) 286 1.19 (1.03-1.36) 61 1.34 (0.99-1.81)
Hispanic 72,785 309 1.19 (1.05-1.35) 235 1.20 (1.04-1.38) 59 1.40 (1.05-1.87)
Pheterogeneity = .57
Contralateral IBCe White 971,003 3134 1.00 2556 1.00 363 1.00
Black 126,291 446 1.18 (1.07-1.31) 322 1.07 (0.95-1.20) 92 1.97 (1.55-2.52)
Asian 125,104 396 0.97 (0.86-1.10) 306 0.89 (0.78-1.02) 68 1.61 (1.20-2.16)
Hispanic 98,900 292 0.98 (0.87-1.11) 234 0.97 (0.84-1.11) 38 1.13 (0.80-1.60)
Pheterogeneity < .0001
Abbreviations: CI, confidence interval; DCIS, ductal carcinoma in situ; ER, estrogen receptor; IBC, invasive breast cancer; HR, hazard ratio; PR, progesterone 
receptor; SEER, Surveillance, Epidemiology, and End Results.
aSecond IBCs included those positive for ER or PR (ER+ or PR+), those negative for both ER and PR (ER–PR–), and those with no information on ER and PR.
bHRs were adjusted for the following: age (20-39, 40-49, 50-59, 60-69, or ≥70 years) and year of the primary DCIS diagnosis (1990-1999, 2000-2009, or 2010-
2015); registry; treatment for primary DCIS (no surgical treatment, breast-conserving surgery alone, breast-conserving surgery followed by radiation therapy, 
mastectomy, or unknown); and histopathological features of primary DCIS, including the tumor size (<2 cm, 2-5 cm, ≥5 cm, or unknown), grade (well differenti-
ated, moderately differentiated, poorly differentiated, or unknown), histology (comedo, papillary, cribriform, solid, or not otherwise specified), and hormone 
receptor expression (positive, negative, or unknown).
cSubsequent IBCs included ipsilateral IBCs, contralateral IBCs, and subsequent metastatic breast cancers.
dThe analysis included the patients who had been treated with breast-conserving surgery or no surgical treatment for their primary DCIS.
ePatients who had undergone bilateral mastectomy for their primary DCIS were excluded.
TABLE 3. Adjusted HRs of Developing IBC in the Same Quadrant of the Same Breast as the Original DCIS 
and IBC in the Ipsilateral Breast Away From the Original DCIS or the Contralateral Breast According  
to Race and Ethnicity in Women With DCIS in SEER, 1990-2015
Person-y
All Second Invasive Eventsa ER+ or PR+ ER– and PR–
Cases, No. HRb (95% CI) Cases, No. HRb (95% CI) Cases, No. HRb (95% CI)
IBC in ipsilateral breast 
away from original DCIS 
and in contralateral 
breast
White 971,003 4741 1.00 3776 1.00 630 1.00
Black 126,291 755 1.34 (1.24-1.45) 547 1.24 (1.13-1.36) 149 1.93 (1.60-2.40)
Asian 125,104 648 1.06 (0.97-1.17) 497 0.99 (0.89-1.10) 107 1.45 (1.15-1.82)
Hispanic 98,900 489 1.05 (0.95-1.16) 388 1.05 (0.94-1.17) 71 1.14 (0.88-1.47)
Pheterogeneity < .0001
IBC in same quadrant of 
same breast as original 
DCIS
White 709,275 431 1.00 327 1.00 62 1.00
Black 89,081 83 1.51 (1.18-1.93) 63 1.47 (1.10-1.95) 11 1.48 (0.75-2.90)
Asian 86,294 71 1.15 (0.87-1.52) 55 1.16 (0.84-1.59) 13 1.49 (0.75-2.98)
Hispanic 72,785 60 1.16 (0.88-1.54) 47 1.22 (0.89-1.67) 12 1.63 (0.85-3.13)
Pheterogeneity = .80
Abbreviations: CI, confidence interval; DCIS, ductal carcinoma in situ; ER, estrogen receptor; HR, hazard ratio; IBC, invasive breast cancer; PR, progesterone 
receptor; SEER, Surveillance, Epidemiology, and End Results.
aSecond IBCs included those positive for ER or PR (ER+ or PR+), those negative for both ER and PR (ER–PR–), and those with no information on ER and PR.
bHazard ratios were adjusted for the following: age (20-39, 40-49, 50-59, 60-69, or ≥70 years) and year of the primary DCIS diagnosis (1990-1999, 2000-2009, 
or 2010-2015); registry; treatment for primary DCIS (no surgical treatment, breast-conserving surgery alone, breast-conserving surgery followed by radiation 
therapy, mastectomy, or unknown); and histopathological features of primary DCIS, including the tumor size (<2 cm, 2-5 cm, ≥5 cm, or unknown), grade (well 
differentiated, moderately differentiated, poorly differentiated, or unknown), histology (comedo, papillary, cribriform, solid, or not otherwise specified), and 
hormone receptor expression (positive, negative, or unknown).
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recurrence scores. There was no significant racial 
difference in the use of 21-gene assays (Supporting 
Table 3). Recurrence scores varied by race/ethnicity 
(Pheterogeneity = .046-.057; Table 4). In comparison with 
white women, the risk of subsequent ER+ IBC with a 
recurrence score of 26 or higher was increased in black 
women (HR, 1.38; 95% CI, 1.00-1.92). Using the 
developed cutoffs for intermediate and high recurrence 
risk, we observed a similar result for black women (HR, 
1.29; 95% CI, 1.00-1.67). There was no significant dif-
ference in Asian and Hispanic women in comparison 
with white women in the risk of developing aggressive 
ER+ IBC defined by recurrence scores.
DISCUSSION
Our prior analysis of the 1990-2009 SEER data dem-
onstrated a significantly higher risk of subsequently 
developing IBC in black women with DCIS than white 
counterparts.5 Using immunohistochemically assessed 
tissue markers and 21-gene recurrence scores, the current 
study extends this finding to biologically aggressive IBC 
in a population-based, racially diverse group of patients 
with DCIS. Compared with white women, black women 
had a higher risk of developing IBC characterized by 
ER–PR– subtypes and higher recurrence scores in ER+ 
tumors after DCIS. This is consistent with the higher risk 
of developing ER–PR– IBC in the general population of 
black women.13,22,23 Asian women were more likely than 
white women to develop ER–PR– IBC. To our knowl-
edge, this is the only study to date examining racial differ-
ences in subsequent IBC subtypes after DCIS.
Our finding of a higher risk of developing aggressive 
breast cancer in black women with DCIS in comparison 
with white counterparts may have clinical relevance. 
Black women with DCIS are more likely than white 
counterparts to die of breast cancer.11 In the setting of 
IBC, basal-like tumors disproportionately affect African 
American women.13,22,23 Basal-like tumors overlap 
largely with triple-negative tumors, which have a poor 
prognosis. Most ER–PR– breast cancers (73%) are neg-
ative for HER2.16 We observed that the risk of triple- 
negative breast cancer was nearly doubled after DCIS in 
black women compared with white women. Therefore, a 
higher risk of developing ER–PR– IBC in black women 
with DCIS may contribute to their worse survival.
Two distinct types of ipsilateral breast cancer 
recurrence have been proposed: true local recurrences 
and new ipsilateral primary tumors.17,24,25 They are gen-
erally distinguished from each other on the basis of both 
histopathology and location.17,26,27 True recurrences have 
a histopathology similar to that of primary tumors and 
are close to the primary tumor bed. True recurrences may 
reflect regrowth of clonogenic cells that have not been 
completely removed by local treatment. New primary 
IBCs are independent of the original breast cancer and 
have different clinical features and a different progno-
sis than true recurrences.17,26,27 The development of new 
primary IBC has been considered a result of a genetic 
predisposition to breast cancer and is associated with 
higher occurrences of contralateral IBC.28 We observed 
that the risk of developing IBC in the ipsilateral breast 
away from the original DCIS and contralateral breasts, 
particularly hormone receptor–negative subtypes, was 
significantly increased in black women. This indicates 
an underlying genetic susceptibility to breast cancer, 
early-life behavioral exposures, and/or their interactions 
TABLE 4. Multivariable-Adjusted HRs for Higher Levels of 21-Gene Recurrence Scores for Early-Stage, 
Hormone Receptor–Positive Invasive Breast Cancer Among Women With DCIS in SEER, 1990-2015
Person-y
Recurrence Scores
<18 ≥18 <26 ≥26
Cases, No. HRa (95% CI) Cases, No. HRa (95% CI) Cases, No. HRa (95% CI) Cases, No. HRa (95% CI)
White 1,018,475 421 1.00 421 1.00 602 1.00 240 1.00
Black 129,931 58 1.11 (0.84-1.46) 68 1.29 (1.00-1.67) 84 1.13 (0.90-1.42) 42 1.38 (1.00-1.92)
Asian 128,657 77 1.37 (1.07-1.75) 57 0.97 (0.73-1.28) 97 1.19 (0.96-1.48) 37 1.11 (0.78-1.57)
Hispanic 102,614 50 1.17 (0.87-1.57) 32 0.71 (0.50-1.02) 64 1.03 (0.80-1.34) 18 0.71 (0.44-1.14)
Pheterogeneity = .046 Pheterogeneity = .057
Abbreviations: CI, confidence interval; DCIS, ductal carcinoma in situ; HR, hazard ratio; SEER, Surveillance, Epidemiology, and End Results.
aHazard ratios were adjusted for the following: age (20-39, 40-49, 50-59, 60-69, or ≥70 years) and year of the primary DCIS diagnosis (1990-1999, 2000-2009, 
or 2010-2015); treatment for primary DCIS (no surgical treatment, breast-conserving surgery alone, breast-conserving surgery followed by radiation therapy, 
mastectomy, or unknown); and histopathological features of primary DCIS, including the tumor size (<2 cm, 2-5 cm, ≥5 cm, or unknown), grade (well differenti-
ated, moderately differentiated, poorly differentiated, or unknown), histology (comedo, papillary, cribriform, solid, or not otherwise specified), and hormone 
receptor expression (positive, negative, or unknown).
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in black women. Prior studies demonstrated that patients 
with true local recurrence had worse survival than those 
with new ipsilateral primary IBC.26,27 Our finding of 
a higher risk of developing ipsilateral IBC in the same 
quadrant of the breast in black patients may contribute 
to their worse survival. Molecular assays (eg, a loss of 
heterozygosity) are more reliable approaches for showing 
clonal relationships between original tumors and ipsi-
lateral IBCs and for distinguishing genetically related 
recurrences from genetically distinct new primaries.24,25 
Racial differences in the distinct types of ipsilateral IBC 
need to be confirmed with molecular methods.
The 21-gene recurrence score is an assay based on 
reverse transcription–polymerase chain reaction that is 
currently applied to early-stage, ER+ IBC to assess the 
prognosis and the likely benefit from chemotherapy in 
addition to endocrine therapy.29 Using the TAILORx-
defined cutoff value of 26,19 we observed that black 
patients with DCIS were more likely than white counter-
parts to subsequently develop aggressive ER+ IBC. Using 
commonly used definitions of intermediate (18-30) and 
high recurrence risks (≥31) generated a similar result. 
This finding was consistent with the racial difference in 
RNA expression–based recurrence scores reported for 
first primary IBC.13-15 A recent analysis of TAILORx 
trial data (including 8189 whites, 693 blacks, 405 
Asians, and 432 others) showed a similar distribution of 
recurrence scores across race groups in patients with 
early-stage, hormone receptor–positive, HER2– IBC 
(with no prior diagnosis of DCIS) and worse survival for 
black patients.30 Our finding needs to be confirmed in 
future studies with a larger number of black patients with 
DCIS who have 21-gene assay results for subsequent IBC.
Biological differences (other than intrinsic subtypes) 
between IBC in black women and white women have been 
identified. In a comprehensive analysis of genomic, tran-
scriptomic, and proteomic data from the Cancer Genome 
Atlas, Huo et al31 found that a number of molecular fea-
tures differed between black and white IBCs after ad-
justments for age and subtypes, including the DNA copy 
number, gene expression, and DNA methylation. Gene 
expression profiling of luminal A and basal-like IBCs iden-
tified 6 genes that were differentially expressed between 
black and white patients and were also associated with 
survival.32 In that study, some poor outcome–associated 
genes were upregulated in cancer-adjacent normal breast 
tissue from black women versus white women. Our data are 
consistent with the idea that black women exhibit genetic 
profiles in nascent tumor cells and/or surrounding nor-
mal cells that create a race-associated biological difference. 
This race-associated genetic difference may occur at the 
earliest stages of carcinogenesis.
We observed a higher risk of developing ER–PR– 
IBC in Asian women with DCIS than white counter-
parts. The clinical relevance of this finding remains to 
be determined because there were no survival differences 
between Asians and whites among patients with DCIS 
from SEER.11 Within Asian American women with their 
first primary IBC, distributions of ER–PR– subtypes have 
been reported to vary across ethnic groups, with the high-
est frequency in South Asians and the lowest frequency in 
Japanese and Chinese.33,34 The number of Asian patients 
with DCIS with subsequent IBC did not allow us to 
examine ethnic differences among Asian women.
This study has limitations. Some variables influenc-
ing DCIS outcomes (eg, surgical margins and endocrine 
therapy) were unavailable. Prior studies reported no racial 
differences in surgical margins or endocrine therapy in 
patients with DCIS.6,9,35,36 Among those who initiated 
endocrine therapy, blacks were more likely than whites to 
be nonadherent to therapy, and Asians were more likely 
to continue therapy.37 Obesity and alcohol consumption 
have been associated with an increased risk of subsequent 
breast cancer in patients with DCIS.38,39 We were unable 
to assess their contributions to racial differences in DCIS 
outcomes. The duration of follow-up was longer in white 
patients than racial minority patients. However, the 
exclusion of patients diagnosed after 2010 did not sig-
nificantly change the race-associated risks (Supporting 
Table 4). Approximately 40% of DCIS cases had no hor-
mone receptor data, and missing indicators were used in 
the analysis. This approach has been demonstrated to 
have no significant impacts on the estimated associations 
between exposures and cancer outcomes when missing-
ness is less than 50%.40 The finding of a race-associated 
higher risk of ER–PR– IBC in all eligible patients was 
consistent with a race-associated higher risk of the hor-
mone receptor status changing from positive to negative 
observed in a subgroup of patients who had complete 
hormone receptor data for both DCIS and subsequent 
IBC (Supporting Table 5). The 21-gene recurrence scores 
were available for only 24% of patients with DCIS who 
subsequently developed early-stage, ER+ IBC. Among 
women with IBC who had no history of DCIS, black 
race has been associated with underutilization of 21-
gene assays and higher recurrence scores.14,15 Therefore, 
a higher risk of recurrence score–defined aggressive IBC 
in black women with DCIS may reflect racial differences 
in testing. However, there was no significant racial differ-
ence in 21-gene testing in our sample.
Original Article
3232 Cancer  September 15, 2019
Overall, we provide evidence for a higher risk of sub-
sequently developing aggressive IBC in black and Asian 
patients with DCIS in comparison with white counterparts. 
This gives us a better understanding of racial influences on 
the risk of IBC after the diagnosis of DCIS and should 
be considered in the management of DCIS. Although the 
molecular and genetic features underlying this higher risk 
remain undiscovered, we have now specified the biologi-
cal context for studying these inherent racial differences. 
Future work will assess its contribution to poorer survival 
in black women with DCIS. A better understanding of 
race-associated biological and nonbiological differences in 
the progression of DCIS will help to distinguish high-risk 
patients with DCIS from low-risk patients with DCIS and 
improve personalized treatment to reduce the dispropor-
tionate burden of breast cancer in black women.
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